Evaluation of Macroprolactin Levels in Females with Hyperprolactinemia

Premjeet Kaur Bhuee; Amandeep Birdi

doi:10.21276/apalm.3607

Authors

Premjeet Kaur Bhuee Department of Biochemistry, Adesh Institute Of Medical Sciences and Research, Bathinda, Punjab, India
Amandeep Birdi Department of Biochemistry, GGS Medical College, Faridkot, Punjab, India

DOI:

https://doi.org/10.21276/apalm.3607

Keywords:

Prolactin isoforms, Polyethylene Glycol, Gel filtration chromatography, Infertility

Abstract

Background: Macroprolactinemia is defined as hyperprolactinemia due to high levels of macroprolactin. The term 'macroprolactinemia' is used when the levels of macroprolactin exceed 60% of the total serum prolactin concentration estimated by polyethylene glycol (PEG) precipitation. Limited data is available on the burden of macroprolactinemia in Indian females. Aim: Find the prevalence of macroprolactin levels in females with hyperprolactinemia. Methods: The study was a hospital-based cross-sectional study with 98 subjects conducted in Central Clinical Lab of Adesh Institute of Medical Sciences and Research. Bathinda, a tertiary care teaching hospital in Punjab, India from July 2024 to April 2025. Subjects included females aged 18 years to 40 years attending the gynaecology OPD for infertility check up whose PrL levels were above the upper limits of laboratory reference range (25 ng/ml in females). Results: A total of 98 patients having a mean age of 29.2 ± 9.6 years were detected to have serum prolactin > 25 ng/mL over a period of July 2024 to April 2025. Further, 12 (12.2%) were detected to have macroprolactinemia. A total of 12 out of 98 patients detected to have macroprolactinemia had serum prolactin in the normal range post-PEG precipitation. Hence, 86 patients (87.75%) continued to have raised serum prolactin levels, even after post-PEG precipitation. Twelve patients were found to have macroprolactinaemia, and the prevalence of macroprolactinemia in hyperprolactinemia females came out to be 12.2%. Conclusion: The occurrence of macroprolactinemia in hyperprolactinemic females is not a rare phenomenon, with a prevalence of 12.2%. Differentiation of subjects with hyperprolactinemia secondary to macroprolactinemia from those with true hyperprolactinemia is clinically essential because the former condition is considered benign and generally requires no further investigation or medication. Further investigations like X-ray and MRI were dropped, which saved time and money of the patient.

References

1. Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the patient with prolactinoma. The Journal of Clinical Endocrinology & Metabolism, 2023;108(9):2400-23. doi: 10.1210/clinem/dgad174

2. Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab. 2013 27:725-742. http://dx.doi.org/10.1016/j.beem.2013.07.002

3. Sharma LK, Sethi R. Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia. J Lab Physicians 2021:13:353-357.

4. Samson SL, Hamrahian AH, Ezzat S, AACE Neuroendocrine and Pituitary Scientific Committee, American College of Endocrinology (ACE). American Association of Clinical Endocrinologists, American College of Endocrinology Disease State Clinical Review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015;21:1427-1435. http://dx.doi.org/10.4158/EP15938.DSC

5. Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin. Biochem. Rev. 2018 39(1):3-16.

6. Kasum M, Pavičić-Baldani D, Stanić P, Orešković S, Sarić JM, Blajić J, Juras J. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 2014;183:28-32. doi: 10.1016/j.ejogrb.2014.10.013.

7. Biagetti B, Ferrer Costa R, Alfayate Guerra R, Álvarez García E, Berlanga Escalera E, Casals G, et al. Macroprolactin: From laboratory to clinical practice. Endocrinologia, diabetes y nutricion. 2022 69(1):63-69. https://doi.org/10.1016/j.endien.2022.01.001

8. Wallace IR, Satti N, Courtney CH, et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab. 2010 95(7):3268-71.

9. Beda-Maluga K, Pisarek H, Romanowska I, Komorowski J, Świetosławski J, Winczyk K. Ultrafiltration - an alternative method to polyethylene glycol precipitation for macroprolactin detection. Arch Med Sci. 2015;11(5):1001-7. doi: 10.5114/aoms.2015.54854.

10. Chen Y, Wang H, Yang W, Jin W, Yu W, Wang W, et al. A New Method of Using Polyethylene Glycol (PEG) Precipitation of Macroprolactin to Detect Genuine Hyperprolactinemia. J Clin Lab Anal. 2016;30(6):1169-1174. doi: 10.1002/jcla.21999.

11. Sostaric M. Bokulic A, Marijancevic D, Zec I. Optimizing laboratory defined macroprolactin algorithm. Biochem Med (Zagreb). 2019:29:020706.

12. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinology and Metabolism Clinics of North America. 2008;37(1):67-99. doi:10.1016/j.ecl.2007.10.013.

13. Shimatsu A, Hattori N. Macroprolactinemia: Diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012:2012:167132. doi: 10.1155/2012/167132.

14. Sim SL, He T, Tscheliessnig A, Mueller M, Tan RB, Jungbauer A. Protein precipitation by polyethylene glycol: a generalized model based on hydrodynamic radius. J. Biotechnol. 2012 157(2):315-319. doi: 10.1016/j.jbiotec.2011.09.0

15. Lim MH, Ho CKM. Macroprolactin screening in 464 patients with hyperprolactinaemia. The Malaysian journal of pathology. 2022:44(2):261-267.

16. Koniares K, Benadiva C, Engmann L, Nulsen J, Grow D. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep. 2023:4(3):245-250. doi: 10.1016/j.xfre.2023.05.005.

17. Noreen Abbas Sherazi, Mirza Zain Baig, Aysha Habib Khan. Frequency of Macroprolactin in Hyperprolactinemia. J Coll Physicians Surg Pak. 2018;28(2):93-97. doi: 10.29271/jcpsp.2018.02.93.